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A B S T R A C T
Objectives: The purpose of this study was to evaluate the event free survival from major adverse cardiac
events (MACE) for ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease
as a function of whether they underwent infarct-related artery (IRA) only percutaneous coronary
intervention (PCI) or complete revascularization at index admission.
Background: The optimal management of patients with STEMI and multivessel disease while undergoing
primary percutaneous coronary intervention (P-PCI) is uncertain.
Methods and results: STEMI patients with multivessel disease undergoing P-PCI between April 1, 2012,
and March 31, 2014, were subdivided into those who underwent in-hospital complete revascularization
(n = 150) or IRA-only revascularization (n = 156). Complete revascularization was performed during the
index admission of P-PCI. The primary endpoint was a composite of all-cause death, recurrent
myocardial infarction (MI), heart failure, and ischemia-driven revascularization within 24 months.
Patient groups were differed at baseline by gender and prevalence of heart failure. The average door-to-
balloon time was signiﬁcantly higher in the complete revascularization group. The primary endpoint
occurred in 11.0% of the complete revascularization group versus 23% in the IRA-only revascularization
group (hazard ratio: 0.51; 95% conﬁdence interval: 0.34–0.93; p = 0.039). There was a signiﬁcant
reduction in death, a non-signiﬁcant reduction in all primary endpoint components was seen.
Conclusions: In patients presenting for P-PCI with multivessel disease, index admission complete
revascularization signiﬁcantly lowered the rate of the primary composite endpoint at 24 months
compared with treating only the IRA.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Indian Heart Journal
jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/ ih j1. Introduction
Primary percutaneous coronary intervention (P-PCI) is the
treatment of choice for patients with ST-segment elevation
myocardial infarction (STEMI).1 Around 30%, patients with
multi-vessel disease (MVD) have signiﬁcant stenoses seen in
1 or more non-infarct related arteries (N-IRA) during index
angiography, a negative prognostic predictor of long-term
outcome.2 This notwithstanding, treatment of N-IRA lesions is
not recommended by current guidelines unless hemodynamic
compromise or residual ischemia are present.1 Literature reports* Corresponding author at: Center for Health Services Research and Development,
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creativecommons.org/licenses/by-nc-nd/4.0/).give conﬂicting results and sufﬁciently powered randomized3–8
clinical trials are lacking.9,10 The purpose of this study was to
evaluate the strategy of complete revascularization with infarct
related artery (IRA)-only on event free survival from major adverse
cardiac events (MACE) in patients with STEMI treated with primary
PCI.
2. Methods
2.1. Study population
All multivessel disease patients who experienced an STEMI
within 24 h before undergoing PCI in our institution between April
1, 2012, to March 31, 2014, were included in the study, with an
exclusion of patients undergoing PCI for acute occlusion after
coronary angioplasty, were retrospectively analyzed. Diagnostic of complete versus lesion only primary percutaneous coronary
 myocardial infarction, Indian Heart J. (2016), http://dx.doi.org/
 India. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient baseline characteristics.
Characteristics Complete
revascularization
n = 150
Infarct
artery-only
PCI
n = 156
p value
Demographic characteristics
Male 131 (87.3) 114 (73.0) 0.001
Age (years), mean (SD) 64.6 (5.2) 64.1 (5.4) 0.47
Risk factors and comorbidities
BMI (kg/m2), mean (SD) 28.9 (5.5) 28.7 (5.5) 0.50
Smoking status at PCI, n (%) 22 (15.0) 21 (16.6) 0.72
Diabetes, n (%) 39 (26.7) 36 (23.3) 0.72
Hyperlipidemia, n (%) 30 (0.3) 36 (23.2) 0.57
Hypertension, n (%) 110 (75.3) 111 (71.6) 0.50
GFR <30 ml/min 1 (0.7) 1 (0.6) 0.94
Cerebrovascular disease, n (%) 6 (0.4) 3 (0.1) 0.26
GI disease, n (%) 19 (13.0) 24 (15.5) 0.54
COPD, n (%) 4 (2.8) 2 (1.3) 0.37
Cardiac status
Anterior MI, n (%) 28 (19.2) 30 (19.4) 0.78
Unstable angina, n (%) 109 (74.7) 108 (69.7) 0.33
History of MI, n (%) 54 (37.0) 57 (36.8) 0.97
MI status by troponin level, n (%)
Probable MI 79 (52.8) 98 (62.8) 0.07
LVEF by CMR (%), mean (SD) 45.5 (3.9) 46.0 (4.0) 0.23
BMI: body mass index; PCI: percutaneous coronary intervention; GI: gastrointesti-
nal; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction;
LVEF: left ventricular ejection fraction; CMR: cardiac magnetic resonance.
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myocardial ischemia, electrocardiographic evidence of STEMI or
both. MVD deﬁned as the presence of 2 major epicardial coronary
arteries or their major branches with stenosis of at least 70%,
assessed by visual estimation during initial coronary angiography.
All patients were written consented to the procedure. The study
was conducted according to the Declaration of Helsinki and
approved by the Institutional review board.
2.2. Databases, data collection, endpoints, and follow-up
Data from all patients with STEMI were prospectively recorded
in a computerized database as part of the catheterization
laboratory registry, regarding demographic data; pre-procedural
risk factors; periprocedural complications; types of devices used;
an extent of disease and lesions treated. These data were recorded
at the time of the procedure and discharge by catheterization
laboratory personnel. A telephone interviewer-administered
structured questionnaire was used to collect data about MACE.
Telephone interviewers were blinded about which group the
patient belong. The primary endpoint in this study was major
adverse cardiac events (MACE) comprising all-cause mortality,
recurrent MI, heart failure (HF), and ischemic-driven revasculari-
zation by PCI/coronary artery bypass grafting (CABG) at
24 months.
2.3. Statistical analysis
Differences between patients undergoing IRA only and com-
plete revascularization at the time of primary PCI in the prevalence
of various patient risk factors (demographic data, comorbidities,
left ventricular function, hemodynamic state, vessels diseased,
time since onset of symptoms) were tested with Chi-square tests
and Fisher exact tests.
3. Results
3.1. Descriptive statistics
Out of 306 patients with the multi-vessel disease who
underwent angioplasty within 12 h of AMI, 156 (51%) received
IRA-only PCI and 150 (49%) received complete revascularization.
There were more females in the IRA-only PCI group than in the
complete revascularization group (26.93% versus 12.67%,
p = 0.001). Regarding existing comorbidities, the complete group
was more likely to suffer from heart failure, cerebrovascular
disease, gastrointestinal disease, COPD, and diabetes. The
average door to balloon time was signiﬁcantly longer in the
complete PCI group than in IRA-only PCI group (p < 0.001). The
patients in the IRA-only group were more likely to have a history
of MI. The groups were similar concerning smoking status, BMI,
stable and unstable angina, left ventricular ejection fraction and
type of stent used during the procedure. Patients’ baseline
characteristics stratiﬁed by PCI procedural types are presented
in Table 1.
Some angiographic characteristics also differed between the
two groups (Table 2). Regarding angiographic characteristics,
proximal LAD artery involvement were more often in the IRA-only
group (35.06% versus 14.50%) compared to the complete group
(p = 0.15). The total number of stents implanted per patient was
signiﬁcantly higher in the complete group (2.12 versus 1.12,
p < 0.001). None of the patients in either group had more than
three vessels affected.
The groups did not differ signiﬁcantly in the rates of discharge
medication prescriptions (Table 2).Please cite this article in press as: Jayaraj JC, et al. Clinical outcomes
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The average follow-up time was 27.8 (SD = 1.1) months for the
full sample, 28.5 (SD = 1.6) months for the complete revasculari-
zation group and 26.8 (SD = 1.1) months for the IRA-only PCI group
(p = 0.039). In total, 51 MACE occurred during the follow-up period
(17 in the complete group and 34 in the IRA-only group) including
8 patients with MI, 16 with repeat revascularization, 15 with heart
failure and 10 patients that died (Table 3). As the Kaplan–Meier
curves show (Fig. 1), the freedom from MACE at two-year follow-
up was 67.02% in the complete group, compared with 63.84% in the
IRA-only group (p = 0.039).
3.3. Cox proportional hazards model for multivariate predictors
The unadjusted predictors of two year survival (MACE) were
identiﬁed using univariate Cox proportional hazard models
(Table 4). Signiﬁcant predictors (p < 0.05) were the number of
three diseased vessels and hypertension. The ﬁnal model was
developed ﬁrst by selecting all variables with p < 0.05 from the
univariate analysis, and then using backward elimination by
applying the log-likelihood ratio test. The proportional hazard
assumption of the Cox model was tested for the ﬁnal model.
The ﬁnal model was adjusted for the three vessel disease in
reference to two vessel disease and hypertension (Table 5). After
adjusting for these covariates, the hazard of developing MACE was
49% lower in the complete revascularization group as compared to
the IRA-only PCI group (HR = 0.51, 95% CI: 0.34–0.95, p = 0.032).
4. Discussion
The study evaluated the differences in 2-year event free survival
from MACE in patients who underwent complete revascularization
and IRA-only PCI for MVD after STEMI during index admission
between 2012 and 2014. A retrospective cohort study design was
utilized for the study where baseline patient characteristics were
abstracted from the medical records and post-procedural events
established through patient surveys. The ﬁnal sample included
306 patients of which 49% had complete PCI, and 51% had IRA-only of complete versus lesion only primary percutaneous coronary
 myocardial infarction, Indian Heart J. (2016), http://dx.doi.org/
Table 2
Angiographic characteristics of coronary arteries.
Characteristics Complete
revascularization
n = 150
Culprit
artery-only
revascularization
n = 156
p value
Hemodynamic unstability
Unstable 6 (4.0) 5 (3.5) 0.46
Killip class II/III on admission 10 (6.5) 14 (9.0) 0.51
TIMI ﬂow grade 2 in IRA 66 (44.0) 81 (52.0) 0.005
Number of diseased vessels, n (%)
Two 115 (76.7) 116 (74.4) 0.63
Three 35 (23.3) 40 (25.6)
Door to balloon time (min),
mean (SD)
192 (45.2) 163 (30.8) <0.001
Stent approach, n (%)
Radial 113 (75.3) 113 (72.4) 0.56
Femoral 37 (24.7) 43 (27.6)
PCI treated culprit arteries, n (%)
Proximal RCA 28 (18.7) 25 (15.0) 0.54
Mild RCAa 22 (14.7) 16 (10.2) 0.24
LMS 0 (0) 0 (0) –
Proximal LAD 27 (18.0) 29 (18.6) 0.60
Mild LAD 21 (14.0) 14 (9.0) 0.15
Proximal circumﬂex 9 (6.0) 14 (9.0) 0.32
Other arteries 18 (12.0) 26 (16.7) 0.24
PCI treated non-culprit arteries, n (%)
Proximal RCA 24 (12.4) 28 (18.2) 0.65
Mild RCAa 43 (22.3) 19 (12.3) 0.001
LMS 1 (0.5) 2 (1.3) 0.58
Proximal LAD 28 (14.5) 54 (35.1) 0.005
Mild LAD 46 (23.8) 36 (23.4) 0.21
Proximal circumﬂex 30 (21.6) 1 (0.7) <0.001
Other arteries 21 (4.7) 14 (8.1) 0.16
Number of stents placed,
mean (SD)
2.12 (0.5) 1.12 (0.4) <0.001
Non-IRA lesions
CTO 48 (32.0) 52 (33.3) <0.001
Distal or secondary branches 31 (21.0) 28 (18.0) 0.004
Discharge medication, n (%)
Antiplatelets 136 (90.7) 152 (97.4) 0.86
BBs 92 (61.3) 96 (64.0) 0.84
ACEi/ARBs 91 (60.7) 92 (9.0) 0.597
Calcium blockers 37 (24.7) 39 (25.0) 0.971
Statins 1 (0.7) 0 (0.00) 0.302
Diuretics 29 (19.3) 21 (13.5) 0.141
PCI: percutaneous coronary intervention; CTO: chronic total occlusion; RCA: right
coronary artery; LMs: left main stem coronary artery; LAD: left anterior
descending; ACE: angiotensin-converting enzyme.
a Stenosis 70%.
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 10 20 30 40
analysis time
Group = IR A-only  PCI Gro up = Co mplete  PCI
Kaplan-Meier surv ival  es timates
Fig. 1. Event-free survival from MACE by complete revascularization.
Table 4
Multivariable Cox proportional hazards model for MACE.
Variables Hazard ratio p value (95% CI)
Complete PCI (reference: 0.51 0.032 (0.34–0.95)
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selected patients, multi-vessel PCI can be performed with high
procedural success but also that this strategy could lead to reduced
mortality compared with IRA-only PCI. This ﬁnding needs to be
further evaluated in a prospective, randomized trial.
Although we cannot second-guess the intentions of the
operators in deciding on the single versus multivessel PCI because
of the retrospective nature, the differences in baseline andTable 3
Distribution of major cardiac events between complete and IRA-only PCI.
Events Complete
revascularization
n = 150
Infarct
related
artery-only
PCI
n = 156
HR (95%) p value
Total MACE 17 (11.0) 34 (22.0) 0.51 (0.34,0.95) 0.03
RR 5 (3.3) 10 (6.4) 0.53 (0.19,1.40) 0.36
HF 6 (4.0) 11 (7.0) 0.48 (0.16,1.27) 0.18
MI 3 (2.0) 5 (3.2) 0.52 (0.13,2.45) 0.33
Death 3 (2.0) 7 (4.4) 0.35 (0.09,1.64) 0.22
MACE: major adverse cardiac events; MI: myocardial infarction; RR: repeat
revascularization; HF: heart failure.
Please cite this article in press as: Jayaraj JC, et al. Clinical outcomes
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healthier patients (younger, more likely male, less likely to have
diabetes or previous stroke and peripheral vascular disease, more
preserved left ventricular function, and fewer total occlusions or
proximal left anterior descending artery lesion) were treated more
aggressively with the multi-vessel PCI. Most likely, this strategy
may be because of the belief that these patients may have lower
procedural risk than the sicker population.
We found that at index hospitalization for PCI, complete and
IRA-only PCI patients had different baseline proﬁles. For example,
patients in the complete revascularization group had more males,
had higher door-to-balloon time, and were more likely to suffer
from heart failure than those in the culprit artery-only PCI group.
These ﬁndings are consistent with many other many randomized
control studies.2,8,10–12
The current study results showed that patients in the complete
PCI group had 49% lower MACE rate at the mean follow-up of
28 months compared to patients in culprit artery-only PCI group.
This ﬁnding agrees with the systematic reviews.4,3 Furthermore, in
the multivariable analysis we found that hypertension increased
the hazard of developing MACE, which is inconsistent with the
results of the registry study, where hypertension was not reported
as a signiﬁcant predictor of MACE.13 It came out that compared to
having two diseased coronary vessels, having three diseased
vessels increases the chance of MACE when controlling for the
intervention type (complete/culprit) and hypertension, similar to
ﬁndings in the literature.14 Patients in the culprit artery-only PCI
group had more number of three diseased vessels, as was found ininfarct related artery-only PCI)
Three vessel disease
(reference: two vessel disease)
2.31 0.019 (1.14–4.65)
Hypertension 3.11 0.026 (1.14–8.51)
Table 5
Multivariable Cox proportional hazards model for MACE.
Variables Hazard ratio p value (95% CI)
Complete PCI (reference: culprit
artery-only PCI)
0.45 0.032 (0.21–0.93)
Three vessel disease (reference:
two vessel disease)
2.31 0.019 (1.14–4.65)
Hypertension 3.11 0.026 (1.14–8.51)
 of complete versus lesion only primary percutaneous coronary
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revascularization group compared to IRA-only PCI group became
more debatable after the publication of PRAMI trial. In the current
analysis, the event-free survival at the end of the follow-up period
was higher in the complete revascularization group when
compared to IRA-only PCI group. These results are in agreement
with other studies, which showed that complete PCI yields to
better event-free survival rate.4,15,16
However, a study showed that complete PCI leads to worse
clinical outcomes. The reason for a trend toward increased mortality
with complete revascularization during index admission in the
nonrandomized registry studies is likely attributable to case
selection.17
4.1. Study limitations
One of the possible limitations of the study was that this is a
retrospective study comprising non-randomized patients, subject
to selection bias. Importantly, the reason for certain patients
underwent multi-vessel PCI in the acute setting is not known. Only
a prospective, randomized study could address the safety and
efﬁcacy of multi-vessel angioplasty during the peri-infarct period.
In the scarce of such studies to date, however, the current study
results suggest that multivessel PCI strategy should be further
explored. The sample represents responders from a single center
with a modest sample size, indicating that patients who
underwent PCI in other hospitals were not included in the study.
Hence, the results are more applicable to the center where the
study is conducted. The strength of our study was that the
interviewers were blinded about which group the patient belong.
Thus, the assessment of the outcomes was blinded.
5. Conclusions
The current study assessed the difference in 2-year event-free
survival among patients with MVD and STEMI, who had undergone
either complete revascularization or IRA-only PCI. The hazard of
developing MACE was signiﬁcantly reduced in the complete
revascularization group. Three-vessel disease (compared to two-
vessel disease) and hypertension were independent predictors of
MACE. Considering the results and the fact that both of the PCI types
are still in use, more studies are needed to show the advantages and
disadvantages of each type for speciﬁc patient populations.
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